Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen

Journal of Medical Virology

Volumn 79, Issue 11, 2007, Pages 1655-1663

  Hyung, Joon Ahn ^a   Myoung, Soo Kim ^a   Yu, Seun Kim ^a,b   Soon, Il Kim ^a   Kyu, Ha Huh ^a   Man, Ki Ju ^a   Sang, Hoon Ahn ^a   Han, Kwang Hyub ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatitis B surface antigen; Lamivudine; Renal transplantation

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LIVER ENZYME;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HUMAN; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 34748852140     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20980     Document Type: Article

References (28)

1. Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, Grotz WH. 2002. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 16:130-136.
2. Casati S, Campise M, Ponticelli C. 1991. Correction of anaemia with recombinant human erythropoietin despite low serum ferritin. Nephrol Dial Transplant 6:452-454.
3. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. 2002. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36:1246-1252.
4. Crosnier J. 1981. Hepatitis B in haemodialysis: Vaccination against HBS antigen. Proc Eur Dial Transplant Assoc 18:231-240.
5. Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V, Tiollais P, Kreis H, Brechot C. 1988. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 94:151-156.
6. Dienstag JL, Schiff ER, Mitchell M, Casey DE, Jr., Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N. 1999a. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 30:1082-1087.
7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999b. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
8. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology 124:105-117.
9. Fabrizi F, Martin P, Ponticelli C. 2002. Hepatitis B virus and renal transplantation. Nephron 90:241-251.
10. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. 2004. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: Meta-analysis of clinical trials. Transplantation 77:859-864.
11. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. 2005. HBsAg seropositive status and survival after renal transplantation: Metaanalysis of observational studies. Am J Transplant 5:2913-2921.
12. Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sircar R, Steinmann TI, Guttmann RD. 1987. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 44:369-376.
13. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. 2000. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32:635-639.
14. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. 2001. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate- aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 33:403-405.
15. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
16. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
17. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30: 567-572.
18. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172-180.
19. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. 1999. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29:257-263.
20. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
21. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. 2004. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 19:iii72-iii76.
22. Park SK, Yang WS, Lee YS, Jung HH, Chang JW, Choi HJ, Han DJ, Park JS. 2001. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 16:2222-2228.
23. Perrillo RP. 2002. Hepatitis B and renal transplantation: Securing the sword of damocles. Hepatology 36:1041-1045.
24. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N. 2001. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33:424-432.
25. Pirson Y, Alexandre GP, Ypersele C. 1977. Long-term effect of hbs antigenemia on patient survival after renal transplantation. N Engl J Med 296:194-196.
26. Scheuer PJ. 1991. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 13:372-374.
27. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. 2000. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803-806.
28. Thabut D, Thibault V, Bernard-Chabert B, Mouquet C, Di Martino V, Le Calvez S, Opolon P, Benhamou Y, Bitker MO, Poynard T. 2004. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 16:1367-1373.